繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

FDA在设备应用中更容易利用现实世界的证据

2025-12-16 05:13

  • The US FDA will no longer require that identifiable individual patient data be required from applicants when submitting real-world evidence as part of certain medical device applications.
  • Sponsors have been clamoring for the change for some time as the individual patient data requirement was seen as burdensome and unnecessary.
  • The agency said the move means that "meaningful information can be extracted from some big data sources without private, individual information."
  • Since 2016, the FDA said more than 250 premarket authorizations for medical devices included real-world evidence.
  • The agency added it is considering the same change for drugs and biologics applications. 

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。